Literature DB >> 6703446

Model of chronic pancreatitis in the dog.

D R Strombeck, E Wheeldon, D Harrold.   

Abstract

A model of chronic pancreatitis was developed and characterized in the dog. Pancreatitis was produced by infusion of oleic acid through a cannula in the accessory pancreatic duct. Biochemical changes included early and marked increases in serum amylase and lipase activities which returned to base line within 3 weeks, at which time the dogs were clinically normal. In dogs euthanatized within 2 weeks, pathologic changes included massive necrosis and hemorrhage, cystic spaces filled with fluid, and abscesses. Histologic features revealed acute exudative pancreatitis with pancreatic atrophy and fibrosis. In dogs killed between weeks 3 to 12, changes included: marked atrophy with remaining acini surrounded by remnants consisting of collapsed stroma, blood vessels, and pancreatic ducts; marked coarse fibrosis with scattered inflammatory cells and occasional acinar tissue; and large irregular pseudocysts.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6703446

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  3 in total

1.  Iron, zinc, and copper concentration in serum, various organs, and hair of dogs with experimentally induced exocrine pancreatic insufficiency.

Authors:  K Adamama-Moraitou; T Rallis; A Papasteriadis; N Roubies; H Kaldrimidou
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

2.  Bile duct obstruction secondary to chronic pancreatitis in seven dogs.

Authors:  A E Cribb; D C Burgener; K A Reimann
Journal:  Can Vet J       Date:  1988-08       Impact factor: 1.008

3.  Increased canine pancreatic lipase immunoreactivity (cPLI) and 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6'-methylresorufin) ester (DGGR) lipase in dogs with evidence of portal hypertension and normal pancreatic histology: a pilot study.

Authors:  Gonçalo Serrano; Dominique Paepe; Tim Williams; Penny Watson
Journal:  J Vet Diagn Invest       Date:  2021-04-02       Impact factor: 1.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.